Osteoarthritis: Clinical guideline 2003

South African Medical Journal

Volumn 93, Issue 12 II, 2003, Pages 972-990

  Brighton, S ^a   Mody, G M ^a   Tikly, M ^a   Bouwer, D ^a  

^a South African Medical Association   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CAPSAICIN; CELECOXIB; CHONDROITIN SULFATE; CODEINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DIACETYLRHEIN; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSAMINE SULFATE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYALURONIC ACID; IBUPROFEN; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PARACETAMOL; ROFECOXIB; TENOXICAM; TRAMADOL; WARFARIN;

ANALGESIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; CONSTIPATION; DIAGNOSTIC TEST; DIGESTIVE SYSTEM FUNCTION DISORDER; DIGESTIVE SYSTEM PERFORATION; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; EDEMA; EXERCISE; FLATULENCE; FLUSHING; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; HIP OSTEOARTHRITIS; HUMAN; INJECTION PAIN; INTERSTITIAL NEPHRITIS; JOINT RADIOGRAPHY; KIDNEY FAILURE; KNEE ARTHROPLASTY; KNEE OSTEOARTHRITIS; LIVER TOXICITY; NAUSEA AND VOMITING; NEPHROTOXICITY; OCCUPATIONAL THERAPY; OSTEOARTHRITIS; PATHOGENESIS; PATIENT EDUCATION; PEPTIC ULCER; PHYSIOTHERAPY; PRACTICE GUIDELINE; RENOVASCULAR HYPERTENSION; REPRODUCTIVE TOXICITY; RISK FACTOR; SEPSIS; TECHNICAL AID; THROMBOSIS; TOTAL HIP PROSTHESIS; TREATMENT PLANNING; WEIGHT REDUCTION;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FEMALE; HAND; HUMANS; KNEE; MALE; MIDDLE AGED; OBESITY; OSTEOARTHRITIS; PATIENT EDUCATION; PRACTICE GUIDELINES; PREVALENCE; RISK FACTORS; SEX FACTORS;

EID: 0347755239     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (183)

1. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part 1. Osteoarthritis of the hip. Arthritis Rheum 1995; 38: 1535-1540.
2. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Part 11. Osteoarthritis of the knee. Arthritis Rheum 1995; 38: 1541-1546.
3. Altman RD, Hochberg MC, Moskowitz RW, Schnitzer TD. Recommendations for the medical management of osteoarthritis of the hip and knee. 2000 Update. American College of Rheumatology. Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000; 43: 1905-1915.
4. Pendleton A, Arden N, Dougados M, et al. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2000; 59: 936-944.
5. Keuttner K, Goldberg VM, eds. Osteoarthritic Disarders 1995. Rosemont: American Academy of Orthopedic Surgeons, 1995.
6. Altman RD, Alarcon G, Appelrouth D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991; 34: 505-514.
7. Altman RD, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Diagnostic and Therapeutic Committee of the American Rheumatism Association. Arthritis Rheum 1986; 29: 1039-1049.
8. Altman RD, Alarcon C, Appelrouth D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum 1990; 33: 1601-1610.
9. Silman AJ, Hochberg MC. Epidemiology of the Rheumatic Diseases. Oxford: Oxford University Press, 1993.
10. Felson DT. Epidemiology of osteoarthritis. In: Brandt KD, Doherty M, Lohmander LS, eds. Osteoarthritis. New York: Oxford University Press, 1998.
11. Val Saase JL, Van Romunde LK, Cats A, Vandenbroucke JP, Valkenburg HA. Epidemiology of osteoarthritis: Zoetermeer survey. Comparison of radiological osteoarthritis in a Dutch population with that in 10 other populations. Ann Rheum Dis 1989; 48: 271-280.
12. Felson DT, Naimark A, Anderson J, Kazis L, Castelli W, Meenan RF. The prevalence of knee osteoarthritis in the elderly. The Framingham Osteoarthritis Study. Arthritis Rheum 1987; 30: 914-918.
13. McAlindon TE, Snow S, Cooper C, Dieppe PA. Radiographic patterns of osteoarthritis of the knee joint in the community: the importance of the patellofemoral joint. Ann Rheum Dis 1992; 51: 844-849.
14. Lawrence JS, Bremmer JM, Bier F. Osteo-arthrosis. Prevalence in the population and relationship between symptoms and x-ray changes. Ann Rheum Dis 1966; 25: 1-24.
15. Brandt KD, Mankin HJ, Shulman LE. Workshop on etiopathogenesis of osteoarthritis. J Rheumatol 1986; 13: 1126-1160.
16. Doherty M, Joms A, Cawston TE. Osteoarthritis. In: Maddison PJ, Isenberg DA, Woo P, Glass DN, eds. Oxford Textbook of Rheumatology. New York: Oxford University Press, 1998.
17. Brandt KD. Osteoarthritis. In: Fauci AS, ed. Harrison's Principles of Internal Medicine. 14th ed. New York: McGraw Hill, 1998.
18. Sharma L. Propioceptive impairment in knee osteoarthritis. Rheum Dis Clin North Am 1999; 25: 299-314.
19. Nevitt MC, Cummings SR, Lane NE, Genant HK, Pressman AR. Current use of oral estrogen is associated with a decreased prevalence of radiographic hip OA in elderly white women. Arthritis Rheum 1994; 37: Suppl, S212.
20. Hannan MT, Felson DT, Anderson JJ, Naimark A, Kannel WB. Estrogen use and radiographic osteoarthritis OA of the knee in women. The Framingham Osteoarthritis Study. Arthritis Rheum 1990; 33: 525-532.
21. Samanta A, Jones A, Regan M, Wilson S, Doherty M. Is osteoarthritis in women affected by hormonal changes or smoking. Br J Rheumatol 1993; 32: 366-370.
22. Wolfe F, Altman R, Hochberg M, Lane N, Luggan M, Sharp J. Postmenopausal estrogen therapy is associated with improved radiographic scores in OA and RA. Arthritis Rheum 1990; 37: suppl, S231.
23. Solomon L, Beighton F, Lawrence, GS. Osteoarthrosis in a rural South African Negro population. Ann Rheum Dis 1976; 35: 274-278.
24. Fellingham SA, Elphinstone CD, Wittman W. Mseleni joint disease: background and prevalence. S Afr Med 1973; 47: 2173-2180.
25. Solomon L, McLaren P, Irwig L, et al. Distinct type of hip disorder in Mseleni joint disease. S Afr Med J 1986; 69: 15-17.
26. Lubbe AM, Elphinstone CD, Fellingham SA. Mseleni joint disease: food and water supplies. S Afr Med J 1973; 47: 2225-2233.
27. Anderson JJ, Felson DT. Factors associated with osteoarthritis of the knee in the first National Health and Nutrition Examination Survey (NHANES 1). Am J Epidemiol 1988; 128: 179-189.
28. Felson DT, Anderson JJ, Naimark A, Walker AM, Meenan RF. Obesity and knee osteoarthritis. The Framingham Study. Ann Intern Med 1988; 109: 18-24.
29. Felson DT, Zhang Y, Anthony JM, Naimark A, Anderson JJ. Weight loss reduces the risk for symptomatic knee OA in women. The Framingham Study. Ann Intern Med 1992; 116: 535-539.
30. Williams RA, Foulsham BM. Weight reduction in osteoarthritis using phentermine. Practitioner 1981; 225: 231-232.
31. Williams CJ, Jimenez SA. Heredity, genes and osteoarthritis. Rheum Dis Clin North Am 1993; 19: 523-543.
32. Radin EL. Mechanical aspects of osteoarthritis. Bull Rheum Dis 1976; 26: 862-865.
33. Dequeker J, Boonen S, Aerssens J, Westhovens R. Inverse relationship osteoarthritis-osteoporosis: What is the evidence? What are the consequences? Br J Rheumatol 1996; 35: 813-818.
34. Hart DJ, Mootoosamy L, Doyle DV, Spectro TD. The relationship between steoarthritis and osteoporosis in the general population: the Chingford study. Ann Rheum Dis 1994; 53: 158-162.
35. Gevers G, Dequeker J, Martens M, et al. Biochemical characteristics of iliac crest bone in elderly women according to osteoarthritis grade at the hand joints. J Rheumatol 1989; 16: 660-663.
36. Dequeker J, Goris P, Utterhoeven R. Osteoporosis and osteoarthritis (osteoarthrosis): anthropometric distinctions. JAMA 1983; 249: 1448-1451.
37. Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum 1998; 41: 1343-1353.
38. Tiku ML, Liesch JB, Robertson FM. Production of hydrogen peroxide by rabbit articular chondrocytes. J Immunol 1990; 145: 690-696.
39. McAlindon TE, Jacques P, Zhang Y, et al. Do antioxidant micronutrients protect the development and progression of knee osetoarthritis. Arthritis Rheum 1996; 39: 648-656.
40. McAlindon TE, Felson DT, Zhang Y, et al. Relation of dietary intake and serum levels of vitamin D to progression of osteoarthritis of the knee among participants in the Framingham Study. Ann Intern Med 1996; 125: 353-359.
41. Lewkonia RM. Does generalised articular hypermobility predispose to generalised osteoarthritis? Clin Exp Rheumatol 1986; 4: 115-119.
42. Lawrence JS. Rheumatism in cotton operatives. Br J Industr Med 1961; 304: 1269-1272.
43. Hadler NM, Gillings DB, Imbus R, et al. Hand structure and function in an industrial setting. Arthritis Rheum 1978; 21: 210-220.
44. Croft P, Coggon D, Cruddas M, Cooper C. Osteoarthritis of the hip: an occupational disease in farmers. BMJ 1992; 304: 1269-1272.
45. Cooper C, McAlindon T, Coggon D, Egger P, Dieppe P. Occupational activity and osteoarthritis of the knee. Ann Rheum Dis 1994; 53: 90-93.
46. Felson DT, Hannan MT, Naimark A, et al. Occupational physical demands, knee bending and knee osteoarthritis: results from the Framingham Study. J Rheumatol 1991; 18: 1587-1592.
47. Schouten JS, De Bie RA, Swaen G. An update on the relationship between occupational factors and osteoarthritis of the hip and knee. Curr Opin Rheumatol 2002; 14: 89-92.
48. Lindberg H, Ross H, Gadsell P. Prevalence of coxarthrosis in former soccer players: 286 players compared to matched controls. Acta Orthop Scand 1993; 64: 165-167.
49. Ghosh P. Articular cartilage: what it is, why it fails in osteoarthritis, and what can be done about it. Arthritis Care Res 1988; 1: 211-221.
50. Hoaglund FT, Yau AC, Wong WI. Osteoarthritis of the hip and other joints in Southern Chinese in Hong Kong. J Bone Joint Surg 1973; 55A: 545-547.
51. Yelin E. The economics of osteoarthritis. In: Brandt KD, Doherty M, Lohmander LS, eds. Osteoarthritis. New York: Oxford University Press, 1998.
52. Rice D. Estimating the Cost of Illness. (Health Economics Series, 1966, No 6). National Center for Health Statistics, 1966.
53. Rice D. Cost of musculoskeletal conditions. In: Pramer A, Furner S, Rice D, eds. Musculoskeletal Conditions in the US. Chicago: American Academy of Orthopaedics, 1992.
54. Gabriel S, Crowson C, O'Fallon W. Costs of osteoarthritis: estimates from a geographically defined population. J Rheumatol 1995; 22: suppl 43: 23-25.
55. Doherty M, Dougados M. Osteoarthritis: Current treatment strategies. Best Pract Res Clin Rheumatol 2001; 15: 517-656.
56. Doherty M, Dougados M. Evidence-based management of osteoarthritis: practical issues relating to the data. Best Pract Res Clin Rheumatol 2001; 15: 517-525.
57. Barlow J. How to use education as an intervention in osteoarthritis. Best Pract Res Clin Rheumatol 2001; 15: 545-558.
58. O'Reilly S, Doherty M. Lifestyle changes in the management of osteoarthritis. Best Pract Res Clin Rheumatol 2001; 15: 559-568.
59. Hurley M, Walsh N. Physical, functional and other non-pharmacological intervention for osteoarthritis. Best Pract Res Clin Rheumatol 2001; 15: 569-581.
60. Cronan TA, Hay M, Groessl E, et al. The effects of social support and education on health care costs after three years. Arthritis Care Res 1998; 11: 326-334.
61. Silman AJ, Hochberg MC. Epidemiology of the Rheumatic Diseases. Oxford; Oxford University Press, 1993.
62. Felson DT, Zhang Y, Hannan MT et al. Risk factors for incident radiographic knee osteoarthritis in the elderly - the Framingham Study. Arthritis Rheum 1997; 40: 728-733.
63. Spector TD, Hart DJ, Doyle DV. Incidence and progression of osteoarthritis in women with unilateral knee disease in the general population: the effect of obesity. Ann Rheum Dis 1994; 53: 565-568.
64. Messier SP, Loesser RF, Mitchell MN, et al. Exercise and weight loss in obese older adults with knee osteoarthritis: a preliminary study. J Am Geriatr Soc 2000; 48: 1062-1072.
65. Huang MH, Chen CH, Chen TW et al. The effects of weight reduction on the rehabilitation of patients with knee osteoarthritis and obesity. Arthritis Care Res 2000; 13: 398-405.
66. Toda Y, Toda T, Takemura S, Wada T, Morimoto T, Ogawa R. Change in body fat, but not body weight or metabolic correlates of obesity, is related to symptomatic relief in obese patients with knee osteoarthritis after a weight control program. J Rheumatol 1998; 25: 2181-2186.
67. Slemenda C, Brandt KD, Heilman DK, et al. Quadriceps weakness and osteoarthritis of the knee. Ann Intern Med 1997; 127: 97-104.
68. McAlindon TE, Cooper C, Kirwan JR, Dieppe PA. Determinants of disability in osteoarthritis of the knees. Ann Rheum Dis 1993; 52: 258-262.
69. O'Reilly SC, Jones A, Muir KR, Doherty M. Quadriceps weakness in knee osteoarthritis (OA): the effect on pain and disability. Ann Rheum Dis 1998; 57: 588-594.
70. Hurley MV. The role of muscle weakness in the pathogenesis of osteoarthritis. Rheum Dis Clin 1999; 25: 283-299.
71. Minor MA, Hewett JE, Webel RR, et al. Efficacy of physical conditioning exercises in patients with rheumatoid and osteoarthritis. Arthritis Rheum 1989; 32: 1397-1405.
72. Effinfer WH, Burns R, Messier SP, et al. A randomised trial comparing aerobic exercise and resistance with a health education program in older adults with knee osteoarthritis. JAMA 1997; 277: 25-30.
73. Van Barr ME, Assendelft WJ, Dekker J, et al. Effectiveness of exercise therapy in patients with osteoarthritis of the hip or knee: a systematic review of randomised controlled trials. Arthritis Rheum 1999; 42: 1361-1369.
74. Minor MA. Exercise in the treatment of osteoarthritis. Rheum Dis Clin North Am 1990; 25: 397-415.
75. Cushnaghan J, McCarthy C, Dieppe P. Taping the patella medially: a new treatment for osteoarthritis of the knee joint? BMJ 1994; 308: 753-755.
76. Quilty B, Tucker M, Dieppe P. Patello-Femoral Joint Disease Disability, Quadriceps Dysfunction and Response to Physiotherapy. (NHS National R & D Programme, Physical and Complex Disabilities. 1998 Report No. PCD / A1 / 123).
77. Kirkley AEA. The effect of bracing on varus gonarthrosis. J Bone Joint Surg 1999; 81-A: 539-548.
78. Hewett T, Noyes F, Barber-Westin S, Heckman T. Decrease in knee joint pain and increase in function in patients with medial compartment arthrosis: a prospective analysis of valgus bracing. Orthopaedics 1998; 21: 131-138.
79. Keating E, Fans P, Ritter M, Kane J. Use of the lateral heel wedges in the treatment of medial osteoarthritis of the knee. Orthopaedic Reviews 1993; 12: 921-924.
80. Hochberg M, Dougados M. Pharmacological therapy of osteoarthritis. Best Pract Res Clin Rheumatol 2001; 15: 583-593.
81. Ayral X. Injections in the treatment of osteoarthritis. Best Pract Res Clin Rheumatol 2001; 15: 609-626.
82. Hauselmann HJ. Nutripharmaceuticals for osteoarthritis. Best Pract Res Clin Rheumatol 2001; 15: 595-607.
83. Towheed TE, Hochberg MC. A systematic review of randomized controlled trials of pharmacological therapy in patients with osteoarthritis of the knee. Semin Arthritis Rheum 1997; 27: 755-770.
84. Bradley JD, Brandt KD, Katz BF, Kalasinski LA, Ryan SI. Comparison of an anti-inflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 1991; 325: 87-91.
85. Williams HJ, Ward JR, Egger MJ, et al. Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. Arthritis Rheum 1993; 36: 1196-1206.
86. Eccles M, Freemantle N, Mason J, for the North of England Non-Steroidal Anti-Inflammatory Drug Guideline Development Group. North of England Evidence Based Guideline Development Project: summary guideline for non-steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis. BMJ 1998; 317: 526-530.
87. Schlodt FV, Rochling FA, Casey DL, Lee WM. Acetaminophen toxicity in an urban country hospital. N Engl J Med 1997; 337: 1112-1117.
88. Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA 1994; 273: 1845-1850.
89. Hyiek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998; 279: 657-662.
90. Fitzmaurice DA, Murray JA. Potentiation of anticoagulant effect of warfarin. Postgrad Med J 1997; 73: 439-440.
91. Henrich WL, Agodaoa LE, Barret B, et al. Analgesics and the kidney: Summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the National Kidney Foundation. Am J Kidney Dis 1996; 27: 162-165.
92. Garcia Rodriguez LA, Hernandez-Diaz S. The relative risk of upper gastrointestinal complications among users of acetaminophen and non-steroidal anti-inflammatory drugs. Epidemiology 2001; 12: 570-576.
93. Kjaersgaard-Andersen P, Nafei A, Skov O, et al. Codeine plus paracetamol versus paracetamol in longer-term treatment of chronic pain due to osteoarthritis of the hip: a randomised, double-blind, multi-centre study. Pain 1990; 43: 309-318.
94. Boissier C, Perpoint B, Laporte-Simitsidis S, et al. Acceptability and efficacy of two associations of paracetamol with a central analgesic (dextropropoxyphene or codeine): comparison in osteoarthritis. J Clin Pharmacol 1992; 32: 990-995.
95. Dalgin P, and the TPS-OA Study Group. Comparison of tramadol and ibuprofen for the chronic pain of osteoarthritis (abstract). Arthritis Rheum 1997; 40: suppl 9, S86.
96. Roth SH. Efficacy and safety of tramadol HCI in breakthrough muscoloskeletal pain attributed to osteoarthritis. J Rheumatol 1998; 25: 1358-1363.
97. Shamoon M, Hochberg MC. The role of acetaminophen in the management of patients with osteoarthritis. Am J Med 2001; 110: 46S-49S.
98. Altman RD, IAP Study Group. Ibuprofen, acetaminophen and placebo in osteoarthritis of the knee: a six day double-blind study (abstract). Arthritis Rheum 1999; 42: suppl 9, S403.
99. Pincus T, Callahan LF, Wolfe F, et al. Arthrotec compared to acetaminophen: a clinical trial in patients with osteoarthritis of the hip or knee (abstract). Arthritis Rheum 1999; 42: suppl 9, S404.
100. Wolfe F, Zhao S, Lane N. Preference to non steroidal anti-inflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum 2000; 43: 378-385.
101. Pincus T, Swearingen C, Cummins P, Callahan LF. Preference for non-steroidal anti-inflammatory drugs versus acetaminophen and concomitant use of both types of drugs in patients with osteoarthritis. J Rheumatol 2000; 27: 1020-1027.
102. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature 1971; 231: 235-239.
103. Fu JY, Masfereer JL, Seibert K, Raz A, Needleman P. The induction and suppression of prostaglandin H2 synthase (cyclo-oxygenase) in human monocytes. J Biol Chem 1990; 215: 16737-16740.
104. Ayral LJ, Lipsky PE, Brooks P, Abramson SB, Simon LS, Vande Putte LBA. Basic biology and clinical application of specific cyclo-oxygenase - 2 inhibitors. Arthritis Rheum 2000; 43: 4-13.
105. Watson MC, Brookes ST, Kirwan JR, Faulkner A. Non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the knee (Cochrane Review). In: The Cochrane Library. Issue 1, 2000. Oxford: Update Software, 2000.
106. Towheed T, Shea B, Wells G, Hochberg M. Analgesia and non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the hip (Cochrane Review). In: The Cochrane Library. Issue 1, 2000. Oxford: Update Software, 2000.
107. Gotzsche PC. Non-steroidal anti-inflammatory drugs. BMJ 2000; 320: 1058-1061.
108. Scholes Dstergachis A, Penna PM. Non-steroidal anti-inflammatory drug discontinuation in patients with osteoarthritis. J Rheumatol 1995; 22: 708-712.
109. Griffin MR, Ray WA, Schaffner W. Non-steroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 1988; 109: 359-363.
110. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Non-steroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991; 115: 787-796.
111. Smalley WE, Griffin MR. The risks and costs of upper gastro-intestinal disease attributable to NSAIDS. Gastroenterol Clin North Am 1996; 25: 373-396.
112. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of non-steroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991; 115: 787-796.
113. Simons LS, Hatoum HT, Bittman RM, Archambault WT, Polisson RP. Risk factors for serious non-steroidal-induced gastrointestinal complications: regression analysis of the MUCOSA Trial. Fam Med 1996; 28: 204-210.
114. Lanza FL, and the Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenetrology. A guideline for the treatment and prevention of NSAID-induced ulcers. Am J Gastroenterol 1998; 93: 2037-2046.
115. Hernandez-Diaz S, Garcia Rodriguez LA. Epidemiological assessment of the safety of conventional non-steroidal anti-inflammatory drugs. Am J Med 2001; 110: 20S-27S.
116. Nielsen GL, Sorensen HT, Larsen H, Pedersen L. Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case-control study. BMJ 2001; 322: 266-270.
117. Simon LS, Lanza FL, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58365, a novel cyclo-oxygenase 2 inhibitor. Arthritis Rheum 1998; 41: 1591-1602.
118. Celecoxib for arthritis. Med Lett Drugs Ther 1999; 41: 11-12.
119. Bensen WG, Flechter JJ, McMillen JI, et al. Treatment of osteoarthritis with a celecoxib, a cyclo-oxygenase-2 inhibitor: a randomised controlled trial. Mayo Clin Prac 1999; 74: 1095-1105.
120. Ehrich EW, Schnitzer TJ, McIlwain H, et al. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double-blind, placebo controlled pilot study of rofecoxib. J Rheumatol 1999; 26: 2438-2447.
121. Saag K, Van der Heijde D, Fisher C, et al. Rofecoxib, a new cyclo-oxygenase-2 inhibitor, shows sustained efficacy, comparable with other non-steroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Arch Fam Med 2000; 9: 1124-1134.
122. Day R, Morrison B, Luza A, et al. A randomised trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vx ibuprofen in patients with osteoarthritis. Arch Intern Med 2000; 160: 1781-1787.
123. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomised controlled trial. JAMA 1999; 282: 1921-1928.
124. Laine L, Harper S, Simon T, et al. A randomised trial comparing the effect of rofecoxib, a cyclo-oxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology 1999; 117: 776-783.
125. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vx non-steroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. JAMA 2000; 294: 1247-1255.
126. Bombardier C, Laine L, Reicin, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-1528.
127. Lanza FL, and Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. A guideline for the treatment and prevention of NSAID-induced ulcers. Am J Gastroenterol 1998; 93: 2037-2046.
128. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving non-steroidal anti-inflammatory drugs: a randomised double- blind placebo-controlled trial. Ann Intern Med 1995; 123: 241-249.
129. Raskin JB, White RH, Jackson JE, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med 1995; 123: 344-350.
130. Ekstrom P, Carling L, Wetterhus S, et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy: a Nordic multicentre study. Scand J Gastroenterol 1996; 31: 753-758.
131. Yeomans NE, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with non-steroidal anti-inflammatory drug therapy. N Engl J Med 1998; 338: 719-726.
132. Doherty M, Jones A. Topical NSAIDS. In: Brandt KD, Doherty M, Lohmander LS, eds. Osteoarthritis. New York: Oxford University Press, 1998.
133. Dickson DJ. A double-blind evaluation of topical piroxicam gel with oral ibuprofen in osteoathritis of the knee. Curr Ther Res 1991; 49: 199-207.
134. Rothacker D, Difiglio C, Lee I. A clinical trial of 10% trolamine salicylate in osteoarthritis. Curr Ther Res 1994; 55: 584-597.
135. Kageyama T. A double- blind placebo controlled multicenter study of piroxicam 0.5% gel in osteoarthritis of the knee. Eur J Rheumatol Inflamm 1987; 8: 114-115.
136. Brandt KD, Bradley JD. Topical capsaicin cream. In: Brandt KD, Doherty M, Lohmander LS, eds. Osteoarthritis. New York: Oxford University Press, 1998.
137. Altman RD, Aven A, Holmburg CP, et al. Capsaicin cream 0.025% as monotherapy for osteoarthritis: a double-blind study. Semin Arthritris Rheum 1994; 23: 25-33.
138. Deal CI, Schnitzer TJ, Lipstein E, et al. Treatment of arthritis with topical capsaicin: a double-blind trial. Clin Ther 1991; 13: 383.
139. McCarthy GM, McCarty DJ. Effect of topical capsaicin in the therapy of painful osteoarthritis of the hands. J Rheumatol 1992; 19: 604.
140. Friedman DM, Moore ME. The efficacy of intra-articular steroids in osteoarthritis: a double blind study. J Rheumatol 1980; 7: 850-856.
141. Dieppe PA, Sathapatayavongs B, Jones HE, et al. Intra-articular steroids in osteoarthritis. Rheumatol Rehabil 1980; 19: 212-217.
142. Gaffney K, Ledingham J, Perry JD. Intra-articular triamcinolone hexacetonide in knee osteoarthritis: factors influencing the clinical response. Ann Rheum Dis 1995; 54: 379-381.
143. Jones A, Doherty M. Intra-articular corticosteroids are effective in osteoarthritis but there are no clinical predictors of response. Ann Rheum Dis 1996; 55: 475-482.
144. Ravaud P, Moulinier L, Giradeau B, et al. Effects of joint lavage and steroid injections in patients with osteoarthritis of the knee. Arthritis Rheum 1999; 42: 475-482.
145. Creamer P. Intra-articular corticosteroid treatment in osteoarthritis. Curr Opin Rheumatol 1999; 11: 417-421.
146. Miller JH, White J, Norton TH. The value of intra-articular injections in osteoarthritis of the knee. J Bone Joint Surg 1958; 4013: 636-641
147. Wright V, Chandler GN, Morison RA, Hartfall SJ. Intra-articular therapy in osteo-arthritis. Comparison of hydrocortisone acetate and hydrocortisone tertiary-butylacetate. Ann Rheum Dis 1960; 19: 257-261.
148. Friedman DM, Moore ME. The efficacy of intraarticular steroids in osteoarthritis: a double blind study J Rheumatol 1980; 7: 850-856.
149. Gaffney K, Ledingham J, Perry JD. Intra-articular triamcinolone hexacetonide in knee ostroarthritis: factors influencing the clinical response. Ann Rheum Dis 1995; 54: 379-381.
150. Jones A, Doherty M. Intra-articular corticosteroids are effective in osteoarthritis but there are no clinical predictors of response. Ann Rheum Dis 1996; 55: 829-832.
151. Plant MJ, Borg AA, Dziedzic K, et al. Radiographic patterns and response to corticosteroid hip injection. Ann Rheum Dis 1997; 56: 476-480.
152. Sparling M, Malleson P, Wood B. Petty R. Radiographic follow-up of joints injected with triamcinolone hexacetonide for the management of childhood arthritis. Arthritis Rheum 1990; 33: 821-826.
153. Roberts WN, Babcock EA, Breitbach SA, et al. Corticosteroid injection in rheumatoid arthritis does not increase rate of total joint arthroplasty. J Rheumatol 1996; 23: 1001-1004.
154. Balch HW, Gibson JM, El-Ghobarey AF, et al. Repeated corticosteroid injections into knee joint. Rheumatol Rehabil 1997; 16: 137-140.
155. Raynault JP, Buckland-Wright C, Tremblay JL, et al. Clinical trials: impact of IA steroid injections on the progression of knee osteoarthritis. Osteoarthritis Cartilage 2000; 8: suppl A, S16.
156. Dougados M, Gueguen A, Nguyen M, et al. Longitudinal radiological evaluation of osteoarthritis of the knee. J Rheumatol 1992; 19: 378-384.
157. Neustadt DH. Intra-articular therapy for rheumatoid synovitis of the knee: effects of the post-injection rest regimen. Clinical Rheumatology in Practice 1985; 3: 65-68.
158. Chakravarty K, Pharoah PDP, Scott DGI. A randomixed controlled study of post-injection rest following intra-articular steroid therapy for knee synovitis. Br J Rheumatol 1994; 33: 464-478.
159. Lequesne M, Bensasson M, Kemmer C, Amouroux J. Painful juxtameniscal areas in certain arthropathies of the knee and their treatment by juxtameniscal cortisone infiltration. Ann Rheum Dis 1970; 29: 689.
160. Schnitzer T, Posner M, Lawrence I. High strength capsaicin cream for osteoarthritis pain: rapid onset of action and improved efficacy with twice daily dosing. J Clin Rheumatol 1995; 1: 268-273.
161. Seror P, Pluvinage P, d'Andre FL, et al. Frequency of sepsis after local corticosteroid injection (an inquiry of 1 160 000 injections in rheumatological private practice in France). Rheumatology 1999; 38: 1272-1274.
162. Gray RG, Gottlieb NL. Intra-articular corticosteroids: an updated assessment. Clin Orthop 1983; 177: 235-263.
163. Caldwell JR. Intra-articular corticosteroids. Guide to selection and indications for use. Drugs 1996; 52: 507-514.
164. George E. Intra-articular hyaluronan treatment for osteoarthritis. Ann Rheum Dis 1998; 57: 637-640.
165. Maheu E. Hyaluronon in knee osteoarthritis: a review of the clinical trials with Hyalgan. Eur J Rheumatol Inflamm 1995; 15: 17-24.
166. Brandt KD, Smith GN, Simon LS. Intra-articular injection of hyaluronan as treatment for knee osteoarthritis. What is the evidence? Arthritis Rheum 2000; 43: 1192-1203.
167. Dougados M, Nguyen M, Listrat V, Amor B. High molecular weight sodium hyaluronate (Hyalectin) in osteoarthritis of the knee. A one year placebo-controlled trial. Osteoarthritis Cartilage 1993; 1: 97-103.
168. Altman RD, Moskowitz R and the Hyalgan Study. Intra-articular sodium hyaluronic (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomised clinical trial. J Rheumatol 1998; 25: 2203-2212.
169. Bragantini A, Molinaroli F. A pilot study clinical evaluation of the treatment of hip osteoarthritis with hyaluronic acid. Curr Ther Res 1994; 55: 319-330.
170. Hauselman HT. Nutripharmaceutical for osteoarthritis. Best Pract Res Clin Rheumatol 2002; 15: 595-607.
171. Gouze JN, Bordji K, Gulberti S, et al. Interleukin-1β down-regulated the expression of glucuronyltransferase 1, a key enzymes priming glycosaminoglycans biosynthesis. Arthritis Rheum 2001; 44: 351-360.
172. Bassleer C, Rovati L, Franchimont P. Stimulation of proteoglycan production by glycosamine sulphate in chondrocytes isolated from human osteoarthritic articular cartilage in vitro. Osteoarthritis Cartilage 1998; 6: 427-434.
173. Sandy JD, Gamett D, Thompson V, Verscharen C. Chondrocyte-mediated catabolism of aggrecan: aggrecanase-dependent cleavage induced by interleukin-1 or retinoic acid can be inhibited by glucosamine. Biochem J 1998; 335: 59-66.
174. Pipitone VR. Chondroprotection with chondroitin sulphate. Drugs Exp Clin Res 1991; 17: 3-7.
175. Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine-sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001; 357: 151-156.
176. Mazières B, Combe B, Phan Van A, et al. Chondroitin selphate in osteoarthritis of the knee: a prospective, double blind, placebo-controlled multicenter clinical study. J Rheumatol 2001; 28: 171-181.
177. Mazzuca SA, Brandt KD, Lane KA, Katz BP. Knee pain reduces joint space width in conventional standing anteroposterior radiographs of osteoarthritic knees. Arthritis Rheum 2002; 46: 1223-1227.
178. Ngayen M, Dougados M, Berdah L, Amor B. Diacerhein in the treatment of osteoarthritis of the hip. Arthritis Rheum 1994; 37: 529-536.
179. Smith GN Jr, Myers SL, Brandt KD, Mickler EA, Albrecht ME. Diacerhein treatment reduces the severity of osteoarthritis in the canine crociate-deficiency model of osteoarthritis. Arthritis Rheum 1999; 42: 545-554.
180. Molodovan F, Pelletier JP, Jolicoeur FC, Cloutier JM, Martel-Pelletier J. Diacerhein and rhein reduce the ICE-induced IL-1 beta and IL-18 activation in human osteoarthritis cartilage. Osteoarthritis Cartilage 2000; 8: 186-196.
181. Fagnani F, Bouvenot G, Valat JP, et al. Medico-economic analysis of diacerhein with or without standard therapy in the treatment of osteoarthritis. Pharmacoeconomics 1998; 13: 135-146.
182. Dougados M, Nguyen M, Berdah I., Mazieres B, Vignon E, Lequesne M, for the ECHODIAH Investigators Group. Evaluation of the structure - modifying effects of diacerin in hip osteoarthritis. ECHODlAH, a Three Year Placebo Controlled Trial. Arthritis Rheum 2001; 44: 2539-2547.
183. Yasuda K, Majima, T, Tanabe Y, Kaneda K. Long-term evaluation of high tibial osteotomy for medial osteoarthritis of the knee. Bull Hosp Joint Dis 1991; 51: 236-248.